PT2219603E - Piperazinas como agentes antimalariais - Google Patents

Piperazinas como agentes antimalariais Download PDF

Info

Publication number
PT2219603E
PT2219603E PT88456009T PT08845600T PT2219603E PT 2219603 E PT2219603 E PT 2219603E PT 88456009 T PT88456009 T PT 88456009T PT 08845600 T PT08845600 T PT 08845600T PT 2219603 E PT2219603 E PT 2219603E
Authority
PT
Portugal
Prior art keywords
piperazines
antimalaria agents
antimalaria
agents
Prior art date
Application number
PT88456009T
Other languages
English (en)
Portuguese (pt)
Inventor
Kerrie Setiawan
Adam Watkinson
Original Assignee
Acrux Dds Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acrux Dds Pty Ltd filed Critical Acrux Dds Pty Ltd
Publication of PT2219603E publication Critical patent/PT2219603E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT88456009T 2007-11-02 2008-10-31 Piperazinas como agentes antimalariais PT2219603E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98478707P 2007-11-02 2007-11-02

Publications (1)

Publication Number Publication Date
PT2219603E true PT2219603E (pt) 2014-09-02

Family

ID=40590452

Family Applications (2)

Application Number Title Priority Date Filing Date
PT88456009T PT2219603E (pt) 2007-11-02 2008-10-31 Piperazinas como agentes antimalariais
PT88455472T PT2214643E (pt) 2007-11-02 2008-10-31 Sistema de entrega transdérmica para hormonas e esteroides

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT88455472T PT2214643E (pt) 2007-11-02 2008-10-31 Sistema de entrega transdérmica para hormonas e esteroides

Country Status (17)

Country Link
US (5) US20100279988A1 (cg-RX-API-DMAC7.html)
EP (2) EP2214643B1 (cg-RX-API-DMAC7.html)
JP (2) JP2011502172A (cg-RX-API-DMAC7.html)
KR (2) KR20100094495A (cg-RX-API-DMAC7.html)
CN (2) CN101888830B (cg-RX-API-DMAC7.html)
AU (2) AU2008318283B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0819245A2 (cg-RX-API-DMAC7.html)
CA (2) CA2704117C (cg-RX-API-DMAC7.html)
DK (2) DK2219603T3 (cg-RX-API-DMAC7.html)
EA (2) EA019760B1 (cg-RX-API-DMAC7.html)
ES (2) ES2494853T3 (cg-RX-API-DMAC7.html)
MX (2) MX2010004788A (cg-RX-API-DMAC7.html)
NZ (2) NZ585034A (cg-RX-API-DMAC7.html)
PL (2) PL2219603T3 (cg-RX-API-DMAC7.html)
PT (2) PT2219603E (cg-RX-API-DMAC7.html)
WO (2) WO2009055859A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201003553B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR068408A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Pulverizacion de hormonas transdermicas
AR068409A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
JP2011502172A (ja) * 2007-11-02 2011-01-20 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド ホルモンおよびステロイド用の経皮送達システム
US20130253449A1 (en) * 2010-12-07 2013-09-26 Yutoku Pharmaceutical Industries Co., Ltd. Noradrenergic and specific serotonergic antidepressant-containing transdermal patch
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PL2782584T3 (pl) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Naturalne skojarzone hormonalne formulacje i terapie zastępcze
US20150148758A1 (en) * 2012-06-05 2015-05-28 Yutoku Pharmaceutical Industries Co., Ltd., Mirtazapine-containing transdermally-absorbable skin-adhesive preparation
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10201549B2 (en) * 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions
US20150065426A1 (en) * 2013-08-27 2015-03-05 Professional Compounding Centers Of America Testosterone Booster Transdermal Compositions
MX384159B (es) * 2014-05-05 2025-03-14 Repros Therapeutics Inc Formulaciones y métodos para el suministro vaginal de antiprogestinas.
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
ES2874549T3 (es) * 2015-02-27 2021-11-05 Dechra Ltd Estimulación del apetito, control de la pérdida de peso, y tratamiento de la anorexia en perros y gatos
WO2016167545A1 (ko) * 2015-04-13 2016-10-20 주식회사 엘지생활건강 신경전달물질의 배출을 조절하는 성분이 포함된 용해성 마이크로니들
EP3284506B1 (en) 2015-04-13 2021-04-28 LG Household & Health Care Ltd. Soluble microneedle containing ingredient for controlling release of neurotransmitters
HK1251938A1 (zh) 2015-05-18 2019-05-03 敏捷治疗公司 避孕组合物及提高效能和调节副作用的方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10449201B2 (en) * 2015-08-17 2019-10-22 Alpha To Omega Pharmaceutical Consultants, Inc. Transdermal and/or topical delivery system comprising clobazam
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2018031576A1 (en) * 2016-08-08 2018-02-15 Baucom Karan Y Hormone delivery system and method
CN110099688A (zh) * 2016-11-17 2019-08-06 赛途公司 骨骼肌肥大诱导物
KR102436756B1 (ko) * 2017-01-31 2022-08-29 신신제약 주식회사 비스테로이드계 소염진통제와 살리실산 유도체를 포함하는 경피흡수 제제
GB2560365B (en) 2017-03-09 2021-10-20 Brightwake Ltd Improvements relating to apparatus negative pressure wound therapy
CN107929268A (zh) * 2017-12-19 2018-04-20 郑州泰丰制药有限公司 一种含质子泵抑制剂药物的透皮贴剂及其制备方法
WO2019140087A1 (en) * 2018-01-10 2019-07-18 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CN108703942B (zh) * 2018-04-23 2021-04-06 中山大学 载有纳米材料包裹保胎药物的微针给药系统及制备方法
US12186326B2 (en) 2018-07-05 2025-01-07 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
CN110947088A (zh) * 2019-12-06 2020-04-03 广州新济薇娜生物科技有限公司 护眼组合贴片及其制备方法
KR102592892B1 (ko) 2021-03-12 2023-10-23 충남대학교산학협력단 데속시코르티코스테론 글루코사이드를 포함하는 당뇨병 예방 또는 치료용 조성물

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK534178A (da) 1977-12-16 1979-06-17 Interx Research Corp Anticholinerge midler med sektrtionshaemmende virkning
US5196410A (en) * 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
JPH01308225A (ja) * 1988-06-03 1989-12-12 Nissan Chem Ind Ltd 外用医薬組成物
DE69007886T2 (de) * 1989-07-21 1994-11-17 Izhak Blank Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung.
US5276079A (en) * 1991-11-15 1994-01-04 Minnesota Mining And Manufacturing Company Pressure-sensitive poly(n-vinyl lactam) adhesive composition and method for producing and using same
ES2107051T3 (es) * 1992-09-21 1997-11-16 Upjohn Co Formulaciones de proteinas de liberacion sostenida.
AU5294393A (en) * 1992-10-06 1994-04-26 Upjohn Company, The Topical pharmaceutical compositions
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6998138B2 (en) * 1996-02-19 2006-02-14 Acrux Dds Pty. Ltd. Topical delivery of anti-alopecia agents
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US6923983B2 (en) * 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6916487B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of antiemetics
GB9902227D0 (en) * 1999-02-01 1999-03-24 Cipla Limited Pharmaceutical composition for topical administration
ES2209812T3 (es) * 1999-02-05 2004-07-01 Cipla Ltd. Pulverizaciones topicas que contienen una composicion filmogena.
AU6019900A (en) * 1999-11-24 2001-06-04 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine crystals and process for producing the same
JP2003520237A (ja) * 2000-01-19 2003-07-02 アクゾ・ノベル・エヌ・ベー 鬱病及び関連疾患を治療するためのミルトラザピン及びジェピロンを含有する配合剤
NZ533036A (en) * 2001-11-09 2006-04-28 Quadra Logic Tech Inc Compositions comprising a photosensitizer and skin penetration enhancer and their use in photodynamic treatment for alopecia cancer acne psoriasis dermatitis ablation and promoting hair growth
EP1534235B1 (en) * 2002-06-25 2016-07-27 Acrux DDS Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
AUPS317102A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Transdermal aerosol compositions
US7704518B2 (en) * 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
CA2433101A1 (en) * 2003-06-23 2004-12-23 Igor Gonda Method of treatment of a female suffering from androgen insufficiency
MXPA06005743A (es) * 2003-11-19 2007-04-17 Acrux Dds Pty Ltd Metodo y composicion para el tratamiento o profilaxis de trastornos de amiloidosis.
US20080027033A1 (en) * 2003-11-19 2008-01-31 Acrux Dds Pty Ltd Method and Composition for Treatment of Cutaneous Lesions
CN102140090A (zh) 2004-03-15 2011-08-03 武田药品工业株式会社 二肽基肽酶抑制剂
JP4613622B2 (ja) * 2005-01-20 2011-01-19 住友電気工業株式会社 軟磁性材料および圧粉磁心
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
CA2604431A1 (en) * 2005-04-13 2006-10-26 Unimed Pharmaceuticals, Inc. Method of increasing testosterone and related steroid concentrations in women
US20070062517A1 (en) * 2005-05-18 2007-03-22 Barker Nicholas P Oral drug delivery system and methods of use thereof
ES2607454T3 (es) * 2005-06-03 2017-03-31 Acrux Dds Pty Ltd Método y composición para el suministro transdérmico de testosterona
WO2006128255A1 (en) * 2005-06-03 2006-12-07 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
CN102225046A (zh) * 2005-08-05 2011-10-26 努沃研究公司 透皮释药剂型
WO2007044976A2 (en) * 2005-10-12 2007-04-19 Unimed Pharmaceuticals, Llc Improved testosterone gel and method of use
WO2008073684A1 (en) * 2006-12-08 2008-06-19 Lipo Chemicals Inc. Composition for treating aging skin comprising a hydroxycinnamic acid such as p-coumaric acid
JP2011502172A (ja) * 2007-11-02 2011-01-20 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド ホルモンおよびステロイド用の経皮送達システム
JP5675175B2 (ja) * 2009-06-23 2015-02-25 大陽日酸株式会社 オゾン供給装置

Also Published As

Publication number Publication date
DK2214643T3 (da) 2014-05-26
CA2704117C (en) 2015-11-17
AU2008318283B2 (en) 2012-03-29
EA019760B1 (ru) 2014-06-30
US20100297032A1 (en) 2010-11-25
ES2494853T3 (es) 2014-09-16
CN101883556B (zh) 2013-05-29
CA2704117A1 (en) 2009-05-07
CN101883556A (zh) 2010-11-10
ZA201003553B (en) 2011-02-23
CA2704116A1 (en) 2009-05-07
EP2214643A1 (en) 2010-08-11
JP2011502173A (ja) 2011-01-20
CN101888830B (zh) 2013-01-23
EP2214643B1 (en) 2014-04-02
KR20100094983A (ko) 2010-08-27
PL2214643T3 (pl) 2014-09-30
DK2219603T3 (da) 2014-09-01
JP5737942B2 (ja) 2015-06-17
EP2219603B1 (en) 2014-07-16
US20130317122A1 (en) 2013-11-28
AU2008318283A1 (en) 2009-05-07
BRPI0819235A2 (pt) 2017-08-22
KR20100094495A (ko) 2010-08-26
PT2214643E (pt) 2014-05-26
ES2466676T3 (es) 2014-06-10
NZ585033A (en) 2011-12-22
EP2214643A4 (en) 2010-12-01
EP2219603A1 (en) 2010-08-25
KR101662186B1 (ko) 2016-10-04
EA201000746A1 (ru) 2010-10-29
EP2219603A4 (en) 2010-11-17
US20160022820A1 (en) 2016-01-28
WO2009055859A1 (en) 2009-05-07
BRPI0819245A2 (pt) 2016-07-19
WO2009055860A1 (en) 2009-05-07
NZ585034A (en) 2011-08-26
US9078810B2 (en) 2015-07-14
HK1144375A1 (en) 2011-02-18
EA201000747A1 (ru) 2010-10-29
MX2010004789A (es) 2010-07-05
US20100279988A1 (en) 2010-11-04
HK1143091A1 (en) 2011-03-18
CN101888830A (zh) 2010-11-17
MX2010004788A (es) 2010-09-14
AU2008318284B2 (en) 2012-03-22
PL2219603T3 (pl) 2014-10-31
JP2011502172A (ja) 2011-01-20
US20130317462A1 (en) 2013-11-28
AU2008318284A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
PT2219603E (pt) Piperazinas como agentes antimalariais
BRPI0817781A2 (pt) piperazino-diidroteinopirimidinas substituídas com heterociclo
BRPI0811065A2 (pt) Indazóis 5-heteroaril substituídos como inibidores de quinase
CR10926A (es) Nuevas 2-aminooxazolinas como ligandos taar1
BRPI0817061A2 (pt) Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3
BRPI0810462A2 (pt) Derivados de quinolina-carboxamida como antagonistas de p2y12
DK2215092T3 (da) Substitueret piperidino-dihydrothienopyrimidin
BRPI0919295A2 (pt) 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.
DK2054394T3 (da) Piperazinforbindelser med herbicid virkning
DE112008001799B8 (de) Beweglicher Körper
BRPI0811199A2 (pt) Novos sais de piperazina como antagonistas de d3/d2
BRPI0922845A2 (pt) pirazol-4-n-alcoxicarboxamidas como microbiocidas
BRPI1015203A2 (pt) agentes antimicrobianos
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI0807137A2 (pt) Agentes antiparasitários
DK2185142T3 (da) Antiseptiske midler
BRPI0718494A2 (pt) Derivado de fenilsulfamoil benzamida como antagonistas de bradicinina
DE502008001632D1 (de) Karosserieaufbau
IL202666A0 (en) Substituted piperazines
IL205874A0 (en) Piperazines as anti-obesity agents
BRPI0811924A2 (pt) Derivados de butona úteis como agentes refrigerantes
BRPI0806542A2 (pt) Derivados de sulfonamida como inibidores de quimase
BRPI0918062A2 (pt) Tienilaminopirimidinas como fungicidas
BRPI0910991A2 (pt) piperidinas substituídas como compostos terapêuticos
BRPI0812912A2 (pt) Derivados de pirrol como antagonistas de p2y12